Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
0.9506
-0.0294 (-3.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
March 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
March 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
January 17, 2024
Via
Investor Brand Network
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
January 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
January 16, 2024
Via
ACCESSWIRE
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
January 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Completed Type A Meeting with the FDA
January 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
December 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
November 28, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
November 27, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces 1-for-30 Reverse Share Split
November 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
November 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Shareholders Meeting Results
November 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
October 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
September 20, 2023
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
September 19, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.